Thus, a single, once in a lifetime transient composite therapy with concurrently administered BACE1 and/or BACE 2 activators and ISR inhibitors can stop for life the progression of conventional Alzheimer’s disease and preclude its recurrence. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.